Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) – Equities research analysts at William Blair upped their Q2 2018 earnings estimates for Arrowhead Pharmaceuticals in a report released on Monday. William Blair analyst Y. Xu now expects that the biotechnology company will post earnings per share of ($0.20) for the quarter, up from their previous estimate of ($0.24). William Blair also issued estimates for Arrowhead Pharmaceuticals’ Q3 2018 earnings at ($0.20) EPS, Q4 2018 earnings at ($0.21) EPS, FY2018 earnings at ($0.80) EPS, Q1 2019 earnings at ($0.22) EPS, Q2 2019 earnings at ($0.23) EPS, Q3 2019 earnings at ($0.24) EPS, Q4 2019 earnings at ($0.25) EPS, FY2019 earnings at ($0.94) EPS and FY2020 earnings at ($1.21) EPS.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Tuesday, December 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Arrowhead Pharmaceuticals had a negative net margin of 116.17% and a negative return on equity of 40.38%. The company had revenue of $8.71 million during the quarter, compared to analyst estimates of $7.32 million.
Arrowhead Pharmaceuticals (ARWR) opened at $5.16 on Wednesday. Arrowhead Pharmaceuticals has a one year low of $1.42 and a one year high of $6.75. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.63 and a quick ratio of 3.63.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Allianz Asset Management GmbH raised its position in shares of Arrowhead Pharmaceuticals by 2.2% during the fourth quarter. Allianz Asset Management GmbH now owns 462,105 shares of the biotechnology company’s stock worth $1,701,000 after purchasing an additional 9,985 shares during the period. OppenheimerFunds Inc. raised its position in shares of Arrowhead Pharmaceuticals by 110.0% during the fourth quarter. OppenheimerFunds Inc. now owns 6,300,000 shares of the biotechnology company’s stock worth $23,184,000 after purchasing an additional 3,300,000 shares during the period. Wells Fargo & Company MN raised its position in shares of Arrowhead Pharmaceuticals by 237.3% during the fourth quarter. Wells Fargo & Company MN now owns 69,997 shares of the biotechnology company’s stock worth $257,000 after purchasing an additional 49,246 shares during the period. Alps Advisors Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $305,000. Finally, First Manhattan Co. acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $11,707,000. 20.48% of the stock is currently owned by institutional investors.
In other news, COO Bruce D. Given sold 20,000 shares of the firm’s stock in a transaction dated Monday, January 1st. The stock was sold at an average price of $3.69, for a total transaction of $73,800.00. Following the sale, the chief operating officer now owns 948,356 shares of the company’s stock, valued at $3,499,433.64. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 4.60% of the company’s stock.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.